GNLX

Genelux Corp. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website genelux.com
Employees(FY) 22
ISIN US36870H1032

Performance

-15.88%

-9.45%

+19.14%

-31.78%

-82.23%

YTD

-76.77%

Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.

Advanced Technical Analysis

Technical Analysis of GNLX 2024-11-20

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 16 indicating strong downward pressure, while the Oscillators Score of 53 suggests a neutral stance. Overall, the Technical Score of 35 reinforces the bearish outlook, indicating that caution is warranted in the current market environment.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of GNLX

Stock Rank

Recent News & Updates

2024-11-14 16:41
These 2 Strong Buy Penny Stocks Are Set to Triple (or more), Say Analysts(Yahoo Finance)
2024-11-14 03:05
Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates(Globenewswire)
2024-11-06 03:01
Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference(Globenewswire)
2024-10-25 01:01
Highbridge Capital Management LLC Acquires Significant Stake in Genelux Corp(Yahoo Finance)
2024-10-22 23:27
Genelux doses first subject in Phase II trial of NSCLC treatment(Yahoo Finance)
2024-10-22 04:01
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer(Globenewswire)
2024-10-09 04:15
Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit(Globenewswire)
2024-09-03 04:01
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference(Globenewswire)
2024-08-14 09:54
GNLX Stock Earnings: Genelux Beats EPS for Q2 2024(Investorplace)
2024-08-14 04:05
Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates(Globenewswire)
2024-08-12 05:16
Genelux Corporation (GNLX): A Strong Buy According to Hedge Funds(Yahoo Finance)
2024-07-29 19:00
Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024(Globenewswire)
2024-05-23 20:00
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants(Globenewswire)
2024-05-23 04:01
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants(Globenewswire)
2024-05-09 11:53
GNLX Stock Earnings: Genelux Misses EPS for Q1 2024(Investorplace)
2024-05-09 04:25
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates(Globenewswire)
2024-04-25 21:35
Down -48.37% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround(Zacks)
2024-04-22 21:35
Down -45.44% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround(Zacks)
2024-04-04 21:35
After Plunging -26.21% in 4 Weeks, Here's Why the Trend Might Reverse for Genelux Corporation (GNLX)(Zacks)
2024-04-04 00:00
All You Need to Know About Genelux Corporation (GNLX) Rating Upgrade to Buy(Zacks)
2024-04-01 19:52
GNLX Stock Earnings: Genelux Misses EPS for Q4 2023(Investorplace)
2024-03-31 19:00
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update(Globenewswire)
2023-12-15 02:01
Insider Sell Alert: Director James Tyree Offloads 9,000 Shares of Genelux Corp (GNLX)(Yahoo Finance)
2023-11-26 18:00
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer(Globenewswire)
2023-11-14 04:50
Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates(Globenewswire)
2023-10-20 01:22
12 Best Performing Biotech Stocks in 2023(Yahoo Finance)
2023-10-10 21:00
Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment(Prnewswire)
2023-09-19 03:01
Director John Thomas Sells 6667 Shares of Genelux Corp (GNLX)(Yahoo Finance)
2023-09-15 03:03
Director John Smither Sells 900 Shares of Genelux Corp (GNLX)(Yahoo Finance)
2023-09-14 01:21
10% Owner Aladar Szalay Sells 52,616 Shares of Genelux Corp (GNLX)(Yahoo Finance)

Page 1 of 2

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.